Dual antiplatelet agent combination

This page covers all Dual antiplatelet agent combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin), COX-1 (aspirin); P2Y12 receptor (thienopyridine).

Targets

P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin) · COX-1 (aspirin); P2Y12 receptor (thienopyridine)

Marketed (2)

• Ticagrelor plus aspirin · Fujian Medical University · Cardiovascular
  Ticagrelor and aspirin work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet activation and aggregation through different pathways.
• Aspirin and thienopyridine · Associations for Establishment of Evidence in Interventions · Cardiovascular
  Aspirin and thienopyridine work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways.